Apollomics Inc. (NASDAQ:APLM – Get Free Report) shares traded down 1.7% on Wednesday . The stock traded as low as $17.25 and last traded at $17.28. 419,490 shares changed hands during trading, an increase of 1,433% from the average session volume of 27,359 shares. The stock had previously closed at $17.58.
Wall Street Analyst Weigh In
Separately, Weiss Ratings lowered shares of Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Apollomics currently has a consensus rating of “Sell”.
Read Our Latest Research Report on APLM
Apollomics Price Performance
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC bought a new stake in shares of Apollomics Inc. (NASDAQ:APLM – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics at the end of the most recent reporting period. 19.13% of the stock is owned by institutional investors.
About Apollomics
Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.
Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.
Further Reading
- Five stocks we like better than Apollomics
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
